Development and clinical validity of a novel blood‐based molecular biomarker for subclinical acute rejection following kidney transplant-Reference-Cited by-同舟云学术

Development and clinical validity of a novel blood‐based molecular biomarker for subclinical acute rejection following kidney transplant

Published:2018-08-31 Issue:1 Volume:19 Page:98-109
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Friedewald John J.¹,Kurian Sunil M.²,Heilman Raymond L.³,Whisenant Thomas C.⁴,Poggio Emilio D.⁵,Marsh Christopher²,Baliga Prabhakar⁶,Odim Jonah⁷,Brown Merideth M.⁷,Ikle David N.⁸,Armstrong Brian D.⁸,charette jane I.¹,Brietigam Susan S.¹,Sustento‐Reodica Nedjema¹,Zhao Lihui¹,Kandpal Manoj¹,Salomon Daniel R.²,Abecassis Michael M.¹,

Affiliation:

1. Northwestern University Feinberg School of Medicine ChicagoIL USA

2. Scripps Health La JollaCA USA

3. Mayo Clinic PhoenixAZ USA

4. UC San Diego Center for Computational Biology & Bioinformatics San DiegoCA USA

5. Cleveland Clinic ClevelandOH USA

6. Medical University of South Carolina CharlestonSC USA

7. National Institute of Allergy and Infectious Diseases BethesdaMD USA

8. Rho Federal Systems Chapel HillNC USA

Funder

National Institutes of Health

Publisher